20 articles
A major review reveals how inflammaging and immunosenescence synergistically drive colorectal cancer in older adults, reshaping the tumor microenvironment.
A comprehensive review reveals how the senescence secretome suppresses tumors early but drives progression, resistance, and metastasis chronically.
Researchers discover CXCR6+ T cells drive deadly myocarditis from immune checkpoint inhibitors and find potential treatment target.
Blocking CysLTR1 reprograms immunosuppressive neutrophils and reverses resistance to anti-PD1 checkpoint therapy in mice.
Comprehensive review reveals promising new drug targets and immunotherapy approaches for myelofibrosis beyond current JAK inhibitor limitations.
Scientists develop advanced drug delivery methods to detect and eliminate harmful senescent tumor cells that promote cancer spread.
Scientists develop innovative immunotherapy that reprograms multiple immune cell types to attack cancer while reducing side effects.
Scientists discover how brain immune cells help cancer metastases grow and identify a potential drug to block this process.
Flaxseed compounds enhance PD-1 inhibitor effectiveness against breast cancer through gut bacteria modulation and immune system activation.
A growth factor called GDF11 reprograms pro-tumor macrophages by rewiring their metabolism, suppressing hepatocellular carcinoma growth.
Phase 1 trial shows MP0317 activates anti-tumor immunity in solid tumors with a favorable safety profile, supporting combination therapy.
New nanotechnology selectively destroys cancer cell mitochondria, making tumors more vulnerable to T cell attacks across multiple cancer types.
Scientists discover how to unleash macrophages against cancer by targeting cellular checkpoints that normally protect tumors.
Harvard researchers demonstrate that activated macrophages can both trigger immune responses and infiltrate tumors directly.
Scientists engineered a fusion protein that recruits abundant immune cells to cross-present tumor antigens, boosting anticancer immunity in mice.
Researchers find new therapeutic potential in existing medication for treating challenging desmoid tumors.
Scientists discover ALPK1 receptor agonists trigger powerful anti-tumor immunity, offering new immunotherapy approach beyond current treatments.
Scientists reveal how to reprogram immune cells that normally help tumors grow to instead become powerful cancer killers.
New review reveals how targeting mitochondria in cancer cells could overcome immunotherapy resistance and enhance anti-tumor responses.
A gut metabolite produced after chemo reprograms bone marrow immune cells, creating a lasting shield against colorectal cancer liver metastasis.
